Johnson & Johnson / Janssen Clinical Trial Pipeline — 293 Active Studies

Phase 1: 51, Phase 2: 67, Phase 3: 104, Other: 71

Following the separation of the consumer business, Johnson & Johnson's pharmaceutical arm (Janssen) operates one of the strongest oncology and immunology pipelines in the industry. In hematology, Darzalex (daratumumab) for multiple myeloma continues expanding into earlier lines and new combinations, while Carvykti (ciltacabtagene autoleucel), the BCMA CAR-T therapy, advances into earlier myeloma settings. Rybrevant (amivantamab), the EGFR-MET bispecific antibody for NSCLC, is rapidly expanding with combination programs including lazertinib. In prostate cancer, Erleada (apalutamide) and Akeega (niraparib/abiraterone) address different molecular subgroups. Their immunology pipeline spans Stelara (ustekinumab), Tremfya (guselkumab), and a next-generation IL-23/IL-17 portfolio.

• Hematology (multiple myeloma, CAR-T)
• Thoracic oncology (EGFR-MET bispecific)
• Prostate cancer
• Immunology / dermatology (IL-23, IL-17)
• Solid tumor immuno-oncology

• Darzalex (daratumumab) — CD38, multiple myeloma
• Carvykti (ciltacabtagene autoleucel) — BCMA CAR-T
• Rybrevant (amivantamab) — EGFR-MET bispecific, NSCLC
• Erleada (apalutamide) — non-metastatic/metastatic CRPC
• Akeega (niraparib + abiraterone) — HRR-mutated prostate
• Tremfya (guselkumab) — IL-23p19, psoriasis/IBD

J&J's Rybrevant + lazertinib combination represents the most significant competitive threat to Tagrisso (osimertinib) in EGFR-mutant NSCLC. Any company active in lung cancer or multiple myeloma must monitor Janssen's Phase 3 pipeline in those indications.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Johnson & Johnson / Janssen's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Johnson & Johnson / Janssen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.